BiolineRx

Company Overview

Snapshot

Founded in April 2003, BioLineRx operates with 51–200 employees and has raised over $208 million across 18 funding rounds from 10 investors. In November 2024, the company secured a strategic equity investment from Highbridge Capital Management, LLC, alongside a licensing agreement for its APHEXDA product.

Business overview

BioLineRx is a clinical-stage biopharmaceutical company specializing in oncology. The company's pipeline features BL-8040, a platform targeting multiple cancer and hematological indications, and AGI-134, a synthetic immunotherapy under development for solid tumors. BioLineRx systematically identifies, validates, and in-licenses therapeutic candidates that offer advantages over existing treatments or address unmet medical needs. The company collaborates with Novartis on co-development of novel drug candidates and with MSD (Merck in the US and Canada) for a Phase 2a study in pancreatic cancer using BL-8040 and Keytruda. BioLineRx has received FDA biological product designation for AGI-134 and European Commission orphan drug designation for Motixafortide (BL-8040) for pancreatic cancer.

Strategic signal

In April 2026, BioLineRx and Hemispherian AS announced the dosing of the first patient in a Phase 1/2a study of GLIX1 for the treatment of Glioblastoma (GBM). This marks a significant step in advancing a new therapeutic candidate for a challenging cancer, indicating the company's continued focus on pipeline expansion and addressing unmet medical needs in oncology.

Company Intelligence Q&A

What was the outcome of BioLineRx's Q1 2026 financial results?

BioLineRx reported its first quarter 2026 financial results in May 2026, highlighting revenue growth and strategic updates. This follows a period of significant clinical and partnership developments.

What is the latest development regarding GLIX1?

In May 2026, BioLineRx and Hemispherian AS highlighted new data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, demonstrating potent anti-tumor effects in glioblastoma across multiple in-vivo studies, including a temozolomide-resistant model.

What strategic partnership did BioLineRx form for GLIX1 development?

In September 2025, BioLineRx and Hemispherian AS established a joint venture to develop GLIX1, a first-in-class oral small molecule targeting DNA damage response in glioblastoma and other cancers. The collaboration aims to advance GLIX1 through clinical evaluation and commercialization.

What new patent did BioLineRx receive for GLIX1?

In November 2025, BioLineRx received a Notice of Allowance from the USPTO for a key patent covering GLIX1, strengthening its patent protection until 2040 for treating a broad range of cancer types.

What was the outcome of BioLineRx's Q2 2025 financial results?

In August 2025, BioLineRx reported a net loss of $3.9 million for Q2 2025, focusing on pipeline replenishment after the transition of Aphexda commercialization to Gamida Cell. The company is evaluating new development assets and plans to announce them by year-end.